| Assessment Status | Suspended |
| HTA ID | - |
| Drug | Midostaurin |
| Brand | Rydapt® |
| Indication | Midostaurin is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). |
| Assessment Process | |
| Rapid review commissioned | 13/08/2018 |
| Rapid review completed | 10/09/2018 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 19/09/2018 |
| Pre-submission consultation with Applicant | 16/10/2018 |
| NCPE assessment outcome | This appraisal has been suspended until further evidence and analyses are included in a re-submission. An update on the appraisal and associated timelines will be provided in due course. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.